Full-Time

Engineer I

Process Development

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines and therapies

Biotechnology
Healthcare

Entry

Norwood, MA, USA

Position based out of Moderna’s Norwood facility.

Category
Bioinformatics
Computational Biology
Genomics
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • BS/MS degree in Bio/Chemical Engineering, Bio/Chemistry, Pharmaceutical Science, or related field
  • Hands on experience with chromatography, ultrafiltration, normal flow filtration, and development of innovative unit operations
  • Working knowledge of statistical design of experiments (DoE) and analysis of multivariate data
  • Experience with analytics and biophysical characterization of nanoparticles is a plus
  • Knowledge of cGMP, ICH, regulatory guidelines and QbD principles as they apply to risk management and product commercialization
  • Demonstrated background of providing technical support to commercial manufacturing processes, including but not limited to, support of process investigations, implementation of pro-active process modifications and support of post-approval changes is a plus
  • Knowledge of nucleic acid chemistry, lipid chemistry, and biology is a plus
  • Ability to thrive in a diverse and fast paced environment
  • Excellent written and verbal communication skills
Responsibilities
  • Design, execute, and analyze experiments for existing and novel process modes using DoE and statistical modeling
  • Define the process, the critical parameters, and the design space
  • Create high throughput and automated experimental setups
  • Lead experiments to confirm robust process performance across the control space
  • Characterize mRNA properties through collaboration with the analytical team
  • Prepare process descriptions, technical reports, and communicate findings internally and externally as appropriate
  • Collect and share relevant academic literature, leverage external consultants/SMEs, and establish new collaborations with internal groups.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a molecule that provides instructions for cells to produce proteins essential for various biological functions. Their approach involves creating a new class of medicines that leverage mRNA to potentially enhance the discovery, development, and manufacturing of drugs. Unlike traditional methods, which often rely on proteins or other biological materials, Moderna's use of mRNA allows for a more versatile and efficient way to create treatments. The company's goal is to improve patient outcomes by harnessing the power of mRNA to address a wide range of health issues.

Company Stage

Grant

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

N/A

Growth & Insights
Headcount

6 month growth

3%

1 year growth

12%

2 year growth

54%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's expansion into combination vaccines and autoimmune therapies showcases its potential for diversified revenue streams and market leadership.
  • The company's continuous innovation and FDA approvals for updated COVID-19 vaccines highlight its resilience and adaptability in a rapidly changing market.
  • Moderna's educational initiatives, like the free mRNA course, position it as a thought leader and advocate for mRNA technology.

What critics are saying

  • The collapse in demand for COVID-19 vaccines could significantly impact Moderna's revenue and growth prospects.
  • Ongoing class action lawsuits alleging securities fraud could damage Moderna's reputation and financial stability.

What makes Moderna unique

  • Moderna is pioneering the use of mRNA technology to create a new class of medicines, setting it apart from traditional pharmaceutical companies.
  • The company's focus on mRNA as the 'software of life' allows for rapid development and manufacturing of vaccines and therapies, unlike conventional methods.
  • Moderna's ability to secure regulatory approvals for mRNA vaccines beyond COVID-19, such as for RSV, demonstrates its leadership in mRNA technology.

Help us improve and share your feedback! Did you find this helpful?